Retatrutide Phase 3 Trials: Current Status and Expected Timeline (2026 Update)

Retatrutide is one of the most highly anticipated experimental compounds within the domain of obesity and metabolic disease. Developed by Eli Lilly and Company, retatrutide is a tripeptide receptor agonist acting on the GLP-1, GIP and glucagon receptors. Its performance in clinical studies has led many researchers to regard it as a next-generation candidate for obesity.

Investigational compound, not approved. Retatrutide has not been approved by the FDA, MHRA, EMA or other major regulators. It remains under investigation and is not available outside clinical trials. This page is informational and is not medical advice.

The following are some of the most common questions being asked about retatrutide:

• Where is the retatrutide Phase 3 programme up to right now?
• When will the retatrutide Phase 3 trials be finished?
• What is the likely time frame for regulatory submissions?

This article provides information current to June 2026.

What Is Retatrutide?

Retatrutide is an investigational once-weekly injectable compound which works by activating three hormones in the metabolic pathway:

• GLP-1 (Glucagon-Like Peptide-1)
• GIP (Glucose-Dependent Insulinotropic Polypeptide)
• Glucagon

This three-in-one mechanism is believed to affect appetite control, energy use, glucose management and body weight. The addition of glucagon receptor activity is thought to be the reason for the larger effects seen compared with earlier GLP-1 compounds. Our triple-agonist explainer covers this mechanism in more detail.

Overview of the Phase 3 TRIUMPH Programme

The Phase 3 development programme for retatrutide is called TRIUMPH and comprises several large international clinical trials testing efficacy and safety in obesity, type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, osteoarthritis and other obesity comorbidities.

Key studies include:

The entire programme has enrolled thousands of participants around the globe, and is the largest evaluation of retatrutide to date.

TRIUMPH-4: The First Major Phase 3 Success

One of the most notable achievements came when Eli Lilly reported positive results from the TRIUMPH-4 Phase 3 trial.

It assessed individuals with either obesity or overweight along with moderate to severe knee osteoarthritis. Those who received a higher dose of retatrutide experienced an average weight loss close to 29%, accompanied by improvement in both pain and physical function measures.

These results were important because they showed effects extending beyond weight loss alone.

Recent 2026 Updates

Several key developments have occurred in 2026.

Eli Lilly published positive data from its TRANSCEND-T2D-1 Phase 3 study of retatrutide in patients with type 2 diabetes in March 2026. This was associated with significant improvement in blood glucose control alongside weight loss.

More recently, Phase 3 data presented in 2026 demonstrated weight loss of more than 28% at higher doses after around 80 weeks. Some participants lost amounts comparable with those seen after bariatric surgery.

Analysts and obesity specialists have described this as one of the strongest data sets for an obesity compound in the pipeline.

What Phase 3 Trials Are Still Ongoing?

While several milestones have been achieved, the retatrutide development programme has not reached its conclusion. Ongoing trials are examining:

• Long-term cardiovascular effects
• Renal effects
• Obstructive sleep apnoea
• Metabolic dysfunction-associated steatotic liver disease (MASLD)
• Chronic obesity
• Further diabetic populations

This research will provide more insight into the compound through 2026 and beyond.

How Does Retatrutide Compare With Current GLP-1 Therapies?

Retatrutide differs from currently approved medications because it targets three hormone pathways rather than one or two. Researchers believe this may contribute to:

• Greater average weight loss
• Enhanced metabolic effects
• Broader benefits across obesity-related conditions

Despite the achievement of important milestones, there is still more work to do. Several late-stage trials continue to examine:

• Long-term cardiovascular endpoints
• Kidney health
• Obstructive sleep apnoea
• Metabolic dysfunction-associated steatohepatitis (MASH)
• Chronic obesity treatment
• Diabetes populations beyond the initial indications

Results from these trials are anticipated during 2026.

Expected Regulatory Timeline

Retatrutide has yet to gain approval from the FDA, MHRA, EMA or other prominent regulatory agencies. At present it remains under investigation and is not approved for use outside clinical trials.

Taking into consideration the existing data and analyst predictions:

Regulatory authorities will continue evaluating both efficacy and long-term safety data before making approval decisions.

What Should Readers Be Aware of at This Point?

Despite the level of interest in retatrutide, it is essential to keep in mind that:

• The compound is investigational only at this point in time.
• It cannot be used clinically until it receives regulatory approval.
• Phase 3 trials are still being carried out and are gathering long-term data.
• There are no regulatory decisions at this point in time.

Anyone interested in retatrutide should speak with a healthcare provider and seek information from trusted medical and regulatory agencies. The primary sources used on this site are listed on our References page.

Final Word

Retatrutide remains one of the most promising compounds currently in development for obesity. The positive results observed during Phase 3 clinical trials show how useful it might become if approved in the future.

With a number of late-stage studies scheduled to report within 2026 and further regulatory filings anticipated thereafter, the next 12 to 18 months may prove decisive for retatrutide.

Further updates will be published here once new data becomes available.

Research & Medical Disclaimer

This article is provided for general informational and educational purposes only and does not constitute medical, clinical or professional advice. Retatrutide is an investigational compound and has not been approved by the FDA, MHRA, EMA or any other regulatory authority. It is not available for prescription outside of authorised clinical trials.

Trial names, statuses and outcomes described here reflect publicly reported information as of June 2026 and may change as additional data becomes available. Figures such as weight-loss percentages refer to specific trial cohorts and dosing arms and should not be interpreted as expected outcomes for any individual.

Always consult a qualified healthcare professional before making any decisions related to medications, treatment or your health. This page is published under our Editorial Policy and Medical Review Process.